NCT04505657View on ClinicalTrials.gov

Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

September 27, 2021

Conditions
IUCD Complication
Interventions
DRUG

celecoxib plus lidocaine

Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure

DRUG

Celecoxib

Celecoxib 200 mg (Celebrex® 200, Pfizer,USA) administered orally 2 h before the procedure +Sterile water 4 puffs during the procedure

DRUG

lidocaine

placebo to celecoxib administered orally 2 h before the procedure +10% lidocaine spray 4 puffs during the procedure

Trial Locations (1)

81528

Aswan University Hospital, Aswān

All Listed Sponsors
lead

Aswan University Hospital

OTHER

NCT04505657 - Lidocaine Spray Plus Oral Celecoxib for Pain Control During Hysterosalpingography | Biotech Hunter | Biotech Hunter